A pharmaceutical cannabinoid company that spent years building a federally compliant operation - DEA-registered labs, FDA Investigational New Drug applications, Orphan Drug Designation - is now in federal court arguing that the Trump administration's cannabis rescheduling order rewards exactly the businesses it outcompeted on compliance. MMJ International Holdings filed a petition for review on May 28 in the U.S. Court of Appeals for the D.C. Circuit, joining a coalition of four other petitioners challenging the order signed by Acting Attorney General Todd Blanche on April 22. For cannabis operators, investors, and compliance professionals, the case introduces real legal uncertainty around the two most consequential provisions of the rescheduling order: 280E tax relief and the new DEA registration pathway for state-licensed operators.
What the Order Actually Does - and What's Now at Risk
The Blanche order reclassified two categories of cannabis products from Schedule I to Schedule III under the Controlled Substances Act: FDA-approved drug products containing marijuana, and products operated under qualifying state-issued medical marijuana licenses. It took effect immediately upon Federal Register publication on April 28. The administration relied on Section 811(d)(1) of the CSA - a treaty-implementation provision - to bypass the standard notice-and-comment rulemaking process, moving faster than any prior federal cannabis scheduling action.
For state-licensed dispensaries and multi-state operators, the order's most immediate practical effect was the elimination of Section 280E's tax deduction disallowance. That provision has functioned for years as a structural penalty on cannabis businesses: because cannabis remained a Schedule I controlled substance, operators couldn't deduct ordinary business expenses - payroll, rent, cost of goods - the way any other retailer can. The result was effective tax rates that bore no resemblance to what comparable businesses in other sectors paid. Removing 280E exposure was, to put it plainly, worth more to many operators than any other regulatory change on the table.
The order also created an expedited DEA registration pathway for state-licensed cannabis businesses, giving them a faster route to federal legitimacy. That's the provision MMJ finds most objectionable.
The Competitive Injury Argument - and Why It Has Standing Implications
MMJ's core argument is that it was structurally penalized for doing things the right way. The company built a pharmaceutical-grade operation: DEA Schedule I analytical laboratory registration, FDA IND applications, Orphan Drug Designation for Huntington's disease, pharmaceutical soft-gel formulations manufactured under full FDA controls. That's not a small investment of money or time. Now, state-market operators - many of whom built businesses in a federal legal gray zone, explicitly outside the pharmaceutical regulatory framework - receive an expedited on-ramp to the same federal legitimacy MMJ spent years earning through the harder path.
The petition frames this as a "regulatory double standard," arguing the expedited pathway "effectively bypasses the rigorous public-interest standards, criminal-history requirements, and diversion-prevention controls that DEA imposed on pharmaceutical applicants like MMJ." Whether that argument survives Article III standing scrutiny is a separate question - but it's the kind of competitive injury claim that at least gets a court's attention, because it identifies a concrete economic harm tied to a specific government action, not a generalized grievance.
Here's what makes this more than a pharmaceutical company's internal grievance: if the court agrees that the expedited registration pathway is legally defective, it could affect how state operators are ultimately brought into the federal system - not just for this order, but for any successor framework.
The Constitutional Wrinkle That Complicates Everything
MMJ brings an additional argument that sits outside the standard APA challenge playbook. MMJ BioPharma Cultivation had previously sued over the DEA's administrative law judge structure, and - notably - the Department of Justice formally conceded in that case that the multiple layers of removal restrictions governing DEA ALJs "do not comport with the separation of powers and Article II." That's the government acknowledging its own adjudicatory machinery may be constitutionally compromised.
The rescheduling order compounds this problem because an expedited rescheduling hearing is currently scheduled to begin June 29, 2026, before the same administrative structure DOJ has already conceded is constitutionally defective. The petitioners argue the order restructures the scheduling framework while that defect remains unresolved - which creates a procedural tangle the D.C. Circuit will have to engage with regardless of how it feels about the underlying rescheduling policy.
That June 29 hearing date is the most immediate procedural pressure point in the case. If the petitioners file for an emergency stay - and the consolidation of three separate petitions gives the coalition some collective weight - the court could act before that hearing opens. A stay would freeze the order pending full review, which means 280E relief and the new DEA pathway would both be on hold.
What Operators and Investors Should Actually Monitor
The D.C. Circuit has consolidated this petition with two earlier challenges: one filed May 4 by Smart Approaches to Marijuana and the National Drug and Alcohol Screening Association, and one filed May 22 by the attorneys general of Nebraska and Indiana (Louisiana subsequently withdrew). The coalition opposing the order now spans pharmaceutical companies, addiction treatment providers, medical specialists, and state governments - a broader adversarial front than the administration likely anticipated.
For cannabis retailers and multi-state operators who have already begun adjusting financial planning around 280E relief, the litigation creates a real exposure to model around. A stay pending review doesn't mean the order is gone - but it does mean the tax benefit is suspended until the court rules. Vacatur would be worse: it returns cannabis to Schedule I and unwinds both the tax and registration gains entirely.
The near-term procedural milestones worth tracking:
- Any emergency stay motion filed before the June 29 hearing date
- The D.C. Circuit's response to consolidated briefing schedules across the three petitions
- Whether the June 29 rescheduling hearing proceeds or is administratively paused pending court action
- How the court engages with the major questions doctrine argument - which, post-Loper Bright, carries real doctrinal weight when an agency acts at this scale without notice-and-comment
The legal theory that may ultimately do the most damage to the order isn't MMJ's competitive injury claim - it's the major questions doctrine challenge. The Supreme Court's Loper Bright decision significantly curtailed deference to agency statutory interpretation, and using Section 811(d)(1)'s treaty-implementation provision to bypass notice-and-comment rulemaking for a reclassification of this magnitude is exactly the kind of move that doctrine was designed to scrutinize. If the court finds that the administration exceeded its statutory authority, the order doesn't get remanded for a do-over - it gets vacated.
Cannabis businesses that assumed rescheduling was a settled matter should treat this litigation as a live operational risk, not background noise.
